Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axelle Amen

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Opinion in Immunology|September 4, 2025
C1 inhibitor: from complement system to bradykinin angioedemaFederica Defendi, Axelle Amen, Giovanna Clavarino, et al.
Current Opinion in Immunology|August 8, 2025
Eliciting or silencing complement activation: strategies for optimizing monoclonal antibodies functionsAxelle Amen, Nicole Thielens, Chantal Dumestre-Pérard, et al.
Current Opinion in Immunology|September 6, 2025
Complement in systemic lupus erythematosus across time and space: from tolerance to tissue injury and from extracellular to intracellular functionsGiovanna Clavarino, Jeanne Vigne, Marie-Sophie Meuleman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 12, 2024
Development of a New Off-the-Shelf Plasmacytoid Dendritic Cell-Based Approach for the Expansion and Characterization of SARS-CoV-2-Specific T CellsAnthony Maino, Axelle Amen, Joël Plumas, et al.
Microbiology Spectrum|November 20, 2024
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variantsLéa Dépéry, Isabelle Bally, Axelle Amen, et al.
Elife|February 17, 2026
Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of <i>Pseudomonas aeruginosa</i> act through distinct mechanismsJean-Mathieu Desveaux, Eric Faudry, Carlos Contreras-Martel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 13, 2022
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platformChristopher Chevillard, Axelle Amen, Solène Besson, et al.
Elife|January 16, 2025
Target-agnostic identification of human antibodies to <i>Plasmodium falciparum</i> sexual forms reveals cross-stage recognition of glutamate-rich repeatsAxelle Amen, Randy Yoo, Amanda Fabra-García, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Target-agnostic identification of human antibodies to <i>Plasmodium falciparum</i> sexual forms reveals cross stage recognition of glutamate-rich repeatsAxelle Amen, Randy Yoo, Amanda Fabra-García, et al.
NPJ Vaccines|March 30, 2025
RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaquesHélène Letscher, Delphine Guilligay, Gregory Effantin, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Opinion in Immunology|September 4, 2025
C1 inhibitor: from complement system to bradykinin angioedemaFederica Defendi, Axelle Amen, Giovanna Clavarino, et al.
Current Opinion in Immunology|August 8, 2025
Eliciting or silencing complement activation: strategies for optimizing monoclonal antibodies functionsAxelle Amen, Nicole Thielens, Chantal Dumestre-Pérard, et al.
Current Opinion in Immunology|September 6, 2025
Complement in systemic lupus erythematosus across time and space: from tolerance to tissue injury and from extracellular to intracellular functionsGiovanna Clavarino, Jeanne Vigne, Marie-Sophie Meuleman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 12, 2024
Development of a New Off-the-Shelf Plasmacytoid Dendritic Cell-Based Approach for the Expansion and Characterization of SARS-CoV-2-Specific T CellsAnthony Maino, Axelle Amen, Joël Plumas, et al.
Microbiology Spectrum|November 20, 2024
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variantsLéa Dépéry, Isabelle Bally, Axelle Amen, et al.
Elife|February 17, 2026
Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of <i>Pseudomonas aeruginosa</i> act through distinct mechanismsJean-Mathieu Desveaux, Eric Faudry, Carlos Contreras-Martel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 13, 2022
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platformChristopher Chevillard, Axelle Amen, Solène Besson, et al.
Elife|January 16, 2025
Target-agnostic identification of human antibodies to <i>Plasmodium falciparum</i> sexual forms reveals cross-stage recognition of glutamate-rich repeatsAxelle Amen, Randy Yoo, Amanda Fabra-García, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Target-agnostic identification of human antibodies to <i>Plasmodium falciparum</i> sexual forms reveals cross stage recognition of glutamate-rich repeatsAxelle Amen, Randy Yoo, Amanda Fabra-García, et al.
NPJ Vaccines|March 30, 2025
RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaquesHélène Letscher, Delphine Guilligay, Gregory Effantin, et al.
Pageof 2